Abstract
BackgroundIn a study on continuation of adalimumab (ADA) therapy in Japan, the concomitant use of MTX with ADA was associated with higher efficacy and treatment retention rate (1). In Western...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
